<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
AMYLIN PHARMACEUTICALS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.001 par value
------------------------------
(Title of Class of Securities)
032346108
--------------
(CUSIP Number)
Blair M. Flicker, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(908) 524-2527
--------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
October 17, 1995
------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
<TABLE>
SCHEDULE 13D
CUSIP NO. 032346108 PAGE 2 OF 7 PAGES
--------- ----- ----
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson 22-1024240
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / /
(B) / /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
NUMBER OF ------------------------------------------------------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY
EACH 1,955,407
REPORTING ------------------------------------------------------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH
-0-
------------------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
1,955,407
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,955,407
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.99%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
<TABLE>
SCHEDULE 13D
CUSIP NO. 032346108 PAGE 3 OF 7 PAGES
--------- ----- ----
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson Development Corporation 22-2007317
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / /
(B) / /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
NUMBER OF ------------------------------------------------------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY
EACH 1,955,407
REPORTING ------------------------------------------------------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH
-0-
------------------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
1,955,407
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,955,407
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.99%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 4
Page 4 of 7 pages
Items 3, 4 and 5 of the Statement on Schedule 13D filed pursuant to Rule
13d-1 of the Rules and Regulations under the Securities Exchange Act of 1934,
as amended, by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson
& Johnson Development Corporation, a New Jersey corporation ("JJDC"), relating
to the shares of Common Stock, $.001 par value (the "Common Stock") of Amylin
Pharmaceuticals, Inc., are hereby amended as follows:
<PAGE> 5
Page 5 of 7 pages
Item 3. Source and Amount of Funds or Other Consideration:
Item 3 is hereby amended and restated as follows:
On June 20, 1995, JJDC purchased from Amylin Pharmaceuticals, Inc., a
Delaware Corporation (the "Company") 724,638 shares of Common Stock of
the Company for $5.0 million. On September 27, 1995, JJDC purchased
from the Company 1,169,230 shares of Common Stock of the Company for
$9.5 million. On October 17, 1995, JJDC purchased from the Company
61,539 shares of Common Stock of the Company for $0.5 million. No
funds were borrowed to finance the purchases.
Item 4. Purpose of Transaction:
Item 4 is hereby amended and restated as follows:
On June 20, 1995, the Company and Lifescan, Inc., a wholly-owned
subsidiary of J&J, entered into a Collaboration Agreement to develop
and commercialize the Company's lead drug candidate, pramlintide (the
"Collaboration"). In conjunction with the Collaboration Agreement, the
Company also entered into a Stock Purchase Agreement with JJDC and a
Loan and Security Agreement with J&J. In accordance with the terms of
the Stock Purchase Agreement, JJDC purchased 724,638 shares of Common
Stock for $5.0 million.
Subject to the terms of the Stock Purchase Agreement, the Company has
the right to sell additional shares of Common Stock to JJDC in an
aggregate amount of $10.0 million prior to the first milestone of the
Collaboration. Pursuant to such right, on September 27, 1995, JJDC
purchased 1,169,230 shares from the Company for $9.5 million and on
October 17, 1995 purchased 61,539 shares from the Company for $0.5
million. Upon the achievement of certain additional milestones, the
Company also has the right to sell additional shares of its Common
Stock to JJDC for net proceeds of up to $30 million.
<PAGE> 6
Page 6 of 7 pages
Pursuant to the terms of the Loan and Security Agreement, the Company
has agreed to issue to J&J warrants (the "Warrants") to purchase 50,000
shares of Common Stock, at an exercise price of $12.00 per share and
with a ten-year exercise period, for each $1.0 million principal amount
of each Development Loan (as defined in the Loan and Security
Agreement) loaned to the Company thereunder. As of the October 5, 1995,
no Development Loans had been made under the Loan and Security
Agreement.
Pursuant to the terms of the Stock Purchase Agreement, JJDC has agreed
that, until June 2005, or sooner in the event that the Collaboration
Agreement is terminated, it will not acquire any additional securities
of the Company other than pursuant to the Stock Purchase Agreement or
upon exercise of the Warrants. Such restriction shall terminate upon
the occurrence of a change in control of the Company or certain other
events, as described more fully in the Stock Purchase Agreement. JJDC
has also agreed not to sell, transfer or dispose of any shares of
Common Stock for certain time periods, as set forth more fully in the
Stock Purchase Agreement.
Item 5. Interest in Securities of the Issuer:
Item 5 is hereby amended and restated as follows:
As of October 26, 1995, J&J and JJDC each had beneficial ownership of
an aggregate of 1,955,407 shares of Common Stock. Based upon the
shares of Common Stock outstanding as of June 30, 1995, as reported
in the Company's Amendment No. 1 on Form 10-Q/A for the quarter ended
June 30, 1995, and the shares of Common Stock offered pursuant to the
Company's Prospectus dated September 22, 1995, 1,955,407 shares
constitute approximately 6.99% of the outstanding shares of Common
Stock.
<PAGE> 7
Page 7 of 7 pages
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
JOHNSON & JOHNSON
DEVELOPMENT CORPORATION
By: /s/ B.M. Flicker
-------------------
B.M. Flicker
Secretary
Date: October 26, 1995
JOHNSON & JOHNSON
By: /s/ P.S. Galloway
-------------------
P.S. Galloway
Secretary
Date: October 26, 1995
